All In Biotech

Drug Trial Radar · NCT05130450

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)

Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

60

Actual

Start

Nov 18, 2021

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Nov 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.

Conditions

  • Familial Chylomicronemia Syndrome

Interventions

  • OlezarsenDrug

    Olezarsen will be administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Fasting TG at 6 Months (Average of Weeks 23, 25, and 27) Compared to BaselineTime frame: Baseline and 6 months

Locations

27 sites in 11 countries. Site status is shown where the registry gives one.

  • Diabetes/Lipid Management & Research Center

    Huntington Beach, California

  • Excel Medical Clinical Trials, LLC

    Boca Raton, Florida

  • Department of Pharmacy

    Park Ridge, Illinois

  • University of Kansas Medical Center (KUMC)

    Kansas City, Kansas

  • CTSI Investigational Pharmacy

    New York, New York

  • Milstein Hospital

    New York, New York

  • IDS Central

    Philadelphia, Pennsylvania

  • Ecogene-21

    Chicoutimi, Quebec, Canada

  • Institute de Recherches Cliniques de Montreal

    Montreal, Quebec, Canada

  • Nathalie Saint-Pierre

    Montreal, Quebec, Canada

  • Clinique des Maladies Lipidiques de Quebec Inc.

    Québec, Quebec, Canada

  • Groupement Hospitalier Est- Pharmacie Secteur Essais Clinique

    Bron, France

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France

  • Pharmacie Hopital de la Conception

    Marseille, France

  • Via Sergio Pansini 5

    Naples, Italy

  • UOC di Farmacia AOUP PAOLO GIACCONE

    Palermo, Italy

  • Azienda Ospedaliero Universitaria Policlinico Umberto I

    Rome, Italy

  • Academisch Medisch Centrum Goederenontvangst Apotheek t.a.v. Kenniscentrum

    Amsterdam, Noor-Holland, Netherlands

  • Oslo Hospital Pharmacy Rikshospitalet

    Oslo, Norway

  • Hospital da Senhora da Oliveira Guimaraes

    Creixomil, Portugal

  • Dra Margarida Falcao Centro Hospitalar Lisboa Ocidental Hospital Egas Moniz

    Lisbon, Portugal

  • Metabolicke centrum MU

    Bratislava, Slovakia

  • Hospital Clínic Barcelona C/ Villarroel

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Apokteket AB

    Malmö, Sweden

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.